keyword
MENU ▼
Read by QxMD icon Read
search

Myeloma multiple 2016

keyword
https://www.readbyqxmd.com/read/30323358/relapse-after-complete-response-in-newly-diagnosed-multiple-myeloma-implications-of-duration-of-response-and-patterns-of-relapse
#1
Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A Gertz, Francis K Buadi, Martha Q Lacy, David Dingli, Amie L Fonder, Suzanne R Hayman, Miriam A Hobbs, Wilson I Gonsalves, Rahma M Warsame, Taxiarchis Kourelis, Yi Lisa Hwa, Prashant Kapoor, Robert A Kyle, Nelson Leung, Ronald S Go, S Vincent Rajkumar, Shaji K Kumar
Achieving a complete response (CR) is associated with improved overall survival (OS) in multiple myeloma (MM), but data on duration of CR (DurCR) are limited. We evaluated 351 patients (2004-2016), achieving CR with first-line therapy. Patients with sustained DurCR ≥ 24 months (n = 177) had better OS; 150 vs. 81 months, p < 0.001. DurCR ≥ 24 months remained a significant predictor for OS (HR: 0.3, 95% CI: 0.2-0.5, p < 0.001) after adjusting for age, revised ISS stage, transplant and maintenance therapy...
October 15, 2018: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/30295258/-chromosomal-abnormalities-associated-with-clinical-outcome-in-patients-with-newly-diagnosed-multiple-myeloma
#2
Hai-Min Chen, Wei Wei, Rong Peng, Hao-Tian Shi, Xiao-Ling Chen, Fan Zhou
OBJECTIVE: To investigate the prognostic value of karyotypic abnormalities in evaluation of prognosis of patients with multiple myeloma. METHODS: The clinical and laboratory data of patients with newly diagnosed multiple myeloma (NDMM) were retrospectively analyzed in our hospital from May 2010 to May 2016. Patients who carried t(4; 14), t(14; 16) or 17P- (at least one of them) were defined as the patients with high-risk karyotype, whereas patients characterized by the absence of the above-mentioned abnormalities were defined as patients with standard-risk karyotype...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/30295257/-clinical-analysis-on-the-therapeutic-efficacy-of-autologous-hematopoietic-stem-cell-transplantation-in-56-multiple-myeloma-patients
#3
Chao-Yu Wang, Bing Xia, Qiao-Yang Ning, Chen Tian, Hai-Feng Zhao, Hong-Liang Yang, Meng-Zhen Li, Zhi-Gang Zhao, Xiao-Fang Wang, Ya-Fei Wang, Yong Yu, Yi-Zhuo Zhang
OBJECTIVE: To evaluate the therapeutic efficacy and prognosis of autologous stem Hematopoietic cell transplantation (auto-HSCT) in multiple myeloma (MM) patients. METHODS: A retrospective study was conducted for 56 patients diagnosed with MM and then received auto-HSCT in our hospital from December 2008 to September 2016. RESULTS: All the patients successfully underwent hematopoietic reconstruction without transplantation-related mortality (TRM)...
October 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/30292736/health-related-quality-of-life-of-patients-with-multiple-myeloma-treated-in-routine-clinical-practice-in-france
#4
Nicolas Despiégel, Chantal Touboul, Alain Flinois, Grèce Saba, Florence Suzan, Sebastian Gonzalez-McQuire, Franck Bonnetain
INTRODUCTION: New therapies for multiple myeloma (MM) have improved life expectancy, but health-related quality of life (HRQoL) data from patients with MM in the real-world setting are lacking. This study, conducted in France, explored the associations between treatment outcomes and HRQoL in patients with MM. PATIENTS AND METHODS: This observational, cross-sectional, multicenter study enrolled patients (≥ 18 years old) with symptomatic MM who had consulted a physician at least once between February and March 2016...
September 5, 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/30254762/renal-dysfunction-and-recovery-following-initial-treatment-of-newly-diagnosed-multiple-myeloma
#5
Benjamin A Derman, Jochen Reiser, Sanjib Basu, Agne Paner
Introduction: Renal insufficiency (RI) in Multiple Myeloma (MM) portends a higher tumor burden and worse prognosis. Reversal of RI in newly diagnosed MM (NDMM) improves patient outcomes, but it is unknown if there is a disparity in renal recovery in NDMM between African Americans (AA) and non-African Americans. Methods: A retrospective chart review was conducted of 690 patients with NDMM at Rush University Medical Center from 2005 to 2016. 118 patients (59 AA and 59 non-AA) with NDMM and an estimated glomerular filtration rate (eGFR) < 90 mL/min/1...
2018: International Journal of Nephrology
https://www.readbyqxmd.com/read/30243581/the-outcome-of-haplo-identical-transplantation-in-patients-with-relapsed-multiple-myeloma-an-ebmt-cibmtr-report
#6
Firoozeh Sahebi, Laurent Garderet, Abraham S Kanate, Diderik-Jan Eikema, Nina Simone Knelange, Omar F Dávila Alvelo, Yener Koc, Didier Blaise, Qaiser Bashir, José M Moraleda, Peter Dreger, James F Sanchez, Stefan Ciurea, Harry Schouten, Nirav N Shah, Mareike Verbeek, Wolf Rösler, Jose L Diez-Martin, Stefan Schoenland, Anita D'Souza, Nicolaus Kröger, Parameswaran Hari
Allogeneic hematopoietic cell transplantation (allo-HCT) using siblings and matched donors has the potential for long-term disease control in a subset of high-risk multiple myeloma (MM) patients. However, the data on using haploidentical donors in this disease are limited. We conducted a retrospective analysis to examine the outcomes of patients with MM who underwent haploidentical allo-HCT within EBMT/CIBMTR centers. A total of 96 patients underwent haploidentical transplantation between 2008 and 2016. With a median follow up of 24...
September 20, 2018: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/30227761/carfilzomib-based-combination-regimens-are-highly-effective-frontline-therapies-for-multiple-myeloma-and-waldenstr%C3%A3-m-s-macroglobulinemia
#7
Maria Chaudhry, Raphael Steiner, Catherine Claussen, Krina Patel, Hans Lee, Donna Weber, Sheeba Thomas, Chun Feng, Behrang Amini, Robert Orlowski, Lei Feng, Elisabet E Manasanch
Multiple myeloma (MM) and Waldenström's macroglobulinemia (WM) are plasma cell disorders often treated with proteasome inhibitors. Recently, several studies evaluated carfilzomib as an initial treatment for these diseases and reported outstanding clinical outcomes. We conducted a retrospective study to report the efficacy and safety of frontline carfilzomib-based combinations in a standard of care setting. From 2014 until 2016 we identified newly diagnosed MM (n = 54) and WM (n = 6) patients treated with carfilzomib as initial therapy who met study inclusion criteria...
September 19, 2018: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/30220144/-clinical-significance-of-the-ratio-of-serum-beta-ctx-pinp-in-multiple-myeloma-bone-diseases-and-bone-metastases
#8
S W Yang, R J Ma, J J Zhao, X L Yuan, L Jiang, J Yang, P C Lei, Y Zhang, L Zhang, G Liu, F Wang, Z M Zhu
Objective: To explore the clinical significance of serum bone metabolites β C-termianl telopeptide of type Ⅰ collagen(β-CTX), Procollagen type Ⅰ N-terminal peptide(PINP) concentration and ratio of beta -CTX/PINP in multiple myeloma bone disease (MMBD) and bone metastases. Methods: A total of 31 cases of MM, 46 cases of bone metastases and 12 healthy controls were enrolled in the department of hematology, oncology and physical examination center of Henan Provincial People's Hospital respectively from October 2016 to October 2017...
August 28, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
https://www.readbyqxmd.com/read/30119153/efficacy-and-safety-of-lenalidomide-and-dexamethasone-in-patients-with-relapsed-refractory-multiple-myeloma-a-real-life-experience
#9
Nur Soyer, Püsem Patır, Ayşe Uysal, Mustafa Duran, Hatice Demet Ünal, Raika Durusoy, Murat Tombuloğlu, Fahri Şahin, Mahmut Töbü, Filiz Vural, Güray Saydam
Background/aim: In Turkey, lenalidomide plus dexamethasone (RD) has been used to treat relapsed/refractory multiple myeloma (RRMM) since 2010. This retrospective, single-center study evaluated the efficacy and tolerability of RD in patients with RRMM between October 2010 and June 2016. Materials and methods: Patients’ records were reviewed, and overall (OS) and progression-free survival (PFS) were assessed. Results: One hundred and twenty patients (71 males; 59...
August 16, 2018: Turkish Journal of Medical Sciences
https://www.readbyqxmd.com/read/29996124/leptomeningeal-myelomatosis-a-rare-but-devastating-manifestation-of-multiple-myeloma-diagnosed-using-cytology-flow-cytometry-and-fluorescent-in-situ-hybridization
#10
Martin Bommer, Miriam Kull, Veronica Teleanu, Phyllis Schwarzwälder, Manuela Feuring-Buske, Jan Kroenke, Donald Bunjes, Christian Langer
INTRODUCTION: Involvement of the central nervous system in patients with multiple myeloma is a rare event. We evaluated the diagnostic workup and prognosis of patients with leptomeningeal myelomatosis (LMM). METHODS: Between April 2005 and April 2016, we identified 16 cases with LMM. The involvement was diagnosed by magnetic resonance imaging (MRI), cerebrospinal fluid (CSF) cytology as well as flow cytometry. Fluorescence in situ hybridization (FISH) was used in 8/16 cases...
2018: Acta Haematologica
https://www.readbyqxmd.com/read/29986853/impact-of-post-asct-maintenance-therapy-on-outcomes-in-patients-with-newly-diagnosed-multiple-myeloma-in-connect-mm
#11
Sundar Jagannath, Rafat Abonour, Brian G M Durie, Mohit Narang, Howard R Terebelo, Cristina J Gasparetto, Kathleen Toomey, James W Hardin, Lynne Wagner, Amit Agarwal, Shankar Srinivasan, Amani Kitali, E Dawn Flick, Michael Sturniolo, Robert M Rifkin
Autologous stem cell transplantation (ASCT) followed by lenalidomide maintenance therapy is the standard of care for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). Clinical trials show progression-free survival (PFS) benefits, with some studies (Cancer and Leukemia Group [CALGB] trial and meta-analysis) also showing overall survival (OS) benefits, but applicability to real-world clinical settings is unclear. Using data from Connect MM, the largest US-based observational registry of NDMM patients, we analyzed effects of maintenance therapy on long-term outcomes in 1450 treated patients enrolled from 2009 to 2011...
July 10, 2018: Blood Advances
https://www.readbyqxmd.com/read/29950224/-bone-marrow-morphology-of-multiple-myeloma-with-non-bone-related-extramedullary-disease
#12
Di Wu, Wen-Juan Wang, Mei Zhang
OBJECTIVE: To explore the morphological characteristics of bone marrow cells of multiple myeloma with non-bone-related extramedullary disease and thier clinical significance. METHODS: Bone marrow smears, peripheral blood smears and bone marrow biopsy sections as well as thier examination results of 20 cases of multiple myloma with non-bone-related extramedullary disease were collected at initial diagnosis in First Affiliated Hospital of Xi'an Jiaotong University from March 2013 to March 2016, and morphological characterisistes of bone marrow cells were analysed in combination with clinical data...
June 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29950223/-diagnostic-value-of-igf-i-%C3%AE-2-mg-and-sf-for-patients-with-multiple-myeloma-and-their-relationship-with-clinical-staging
#13
Xiao-Ying Wu, Ju-Mei Shi, Yi Tao, Zhong Li
OBJECTIVE: To investigate the diagnostic value of insulin like growth factor I(IGF-I), β2-microglobulin (β2MG) and serum ferritin (SF) in patients with multiple myeloma (MM) and their ralationship with clinical staging. METHODS: Seventy-seven patients with MM treated in Depertment of Hematology of Shanghai 10th hospital and Oncology of Shanghai Armed Police Hospital from August 2016 to June 2017 were enrolled in MM group, at same period 77 healthy volunteers were enrolled in normal control group...
June 2018: Zhongguo Shi Yan Xue Ye Xue za Zhi
https://www.readbyqxmd.com/read/29943829/adipokines-adiposity-and-bone-marrow-adipocytes-dangerous-accomplices-in-multiple-myeloma
#14
REVIEW
Emma V Morris, Claire M Edwards
Obesity has become a global epidemic influencing the establishment and progression of a wide range of diseases, such as diabetes, cardiovascular disease, and cancer. In 2016, International Agency for Research on Cancer reported that obesity is now associated with 13 different cancers, one of which is multiple myeloma (MM), a destructive cancer of plasma cells that predominantly reside in the bone marrow. Obesity is the accumulation of excess body fat, which causes metabolic, endocrine, immunologic, and inflammatory-like changes...
December 2018: Journal of Cellular Physiology
https://www.readbyqxmd.com/read/29890920/granulocyte-colony-stimulating-factor-utilization-postautologous-hematopoietic-stem-cell-transplant-in-multiple-myeloma-patients-does-one-size-fit-all
#15
Emily R Jackson, Jason R Jared, Jennifer K Piccolo, Kaitlin M Woo, Mary S Mably, Michael P Reed, Natalie S Callander
Purpose To evaluate a single institution's experience with granulocyte colony-stimulating factor after autologous hematopoietic stem cell transplant in myeloma patients to identify populations that benefit most from granulocyte colony-stimulating factor administration. Methods Retrospective chart reviews were conducted on patients 18+ years with multiple myeloma that underwent autologous hematopoietic stem cell transplant at UW Health from January 2012 to May 2016. Data collection included demographics, length of stay, time to engraftment, Eastern Cooperative Oncology Group performance status score, and hematopoietic cell transplantation-comorbidity index...
January 1, 2018: Journal of Oncology Pharmacy Practice
https://www.readbyqxmd.com/read/29866475/once-weekly-versus-twice-weekly-carfilzomib-dosing-in-patients-with-relapsed-and-refractory-multiple-myeloma-a-r-r-o-w-interim-analysis-results-of-a-randomised-phase-3-study
#16
Philippe Moreau, Maria-Victoria Mateos, James R Berenson, Katja Weisel, Antonio Lazzaro, Kevin Song, Meletios A Dimopoulos, Mei Huang, Anita Zahlten-Kumeli, A Keith Stewart
BACKGROUND: Twice a week carfilzomib at 27 mg/m2 is approved for treatment of relapsed or refractory multiple myeloma. Phase 1/2 CHAMPION-1, the first study exploring once-weekly carfilzomib dosing, established the maximum tolerated dose at 70 mg/m2 in combination with dexamethasone. We aimed to compare progression-free survival in patients with relapsed and refractory multiple myeloma given once weekly carfilzomib or twice weekly carfilzomib. METHODS: In this prespecified interim analysis of the randomised, open-label, phase 3 A...
July 2018: Lancet Oncology
https://www.readbyqxmd.com/read/29844008/heterogeneity-of-second-line-treatment-for-patients-with-multiple-myeloma-in-the-connect-mm-registry-2010-2016
#17
Sundar Jagannath, Rafat Abonour, Brian G M Durie, Cristina Gasparetto, James W Hardin, Mohit Narang, Howard R Terebelo, Kathleen Toomey, Lynne Wagner, Shankar Srinivasan, Amani Kitali, Lihua Yue, E Dawn Flick, Amit Agarwal, Robert M Rifkin
BACKGROUND: The treatment landscape for multiple myeloma (MM) has undergone recent changes with the regulatory approval of several new therapies indicated for second- and later-line disease. Using data from Connect MM, the largest multisite, primarily community-based, prospective, observational registry of MM patients in the United States, selection of second-line treatments was evaluated during a 5-year period from 2010 to 2016. PATIENTS AND METHODS: Eligible patients were aged ≥ 18 years, had newly diagnosed MM ≤ 2 months before study entry, and were followed for up to 8 years...
July 2018: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/29808907/elotuzumab-monotherapy-in-patients-with-smouldering-multiple-myeloma-a-phase-2-study
#18
Sundar Jagannath, Jacob Laubach, Ellice Wong, Keith Stockerl-Goldstein, Cara Rosenbaum, Madhav Dhodapkar, Ying-Ming Jou, Mark Lynch, Michael Robbins, Suresh Shelat, Kenneth C Anderson, Paul G Richardson
Smouldering multiple myeloma (SMM) is associated with increased risk of progression to multiple myeloma within 2 years, with no approved treatments. Elotuzumab has been shown to promote natural killer (NK) cell stimulation and antibody-dependent cellular cytotoxicity (ADCC) in vitro. CD56dim (CD56dim /CD16+ /CD3- /CD45+ ) NK cells represent the primary subset responsible for elotuzumab-induced ADCC. In this phase II, non-randomized study (NCT01441973), patients with SMM received elotuzumab 20 mg/kg intravenously (cycle 1: days 1, 8; monthly thereafter) or 10 mg/kg (cycles 1, 2: weekly; every 2 weeks thereafter)...
August 2018: British Journal of Haematology
https://www.readbyqxmd.com/read/29800065/global-burden-of-multiple-myeloma-a-systematic-analysis-for-the-global-burden-of-disease-study-2016
#19
Andrew J Cowan, Christine Allen, Aleksandra Barac, Huda Basaleem, Isabela Bensenor, Maria Paula Curado, Kyle Foreman, Rahul Gupta, James Harvey, H Dean Hosgood, Mihajlo Jakovljevic, Yousef Khader, Shai Linn, Deepesh Lad, Lorenzo Mantovani, Vuong Minh Nong, Ali Mokdad, Mohsen Naghavi, Maarten Postma, Gholamreza Roshandel, Katya Shackelford, Mekonnen Sisay, Cuong Tat Nguyen, Tung Thanh Tran, Bach Tran Xuan, Kingsley Nnanna Ukwaja, Stein Emil Vollset, Elisabete Weiderpass, Edward N Libby, Christina Fitzmaurice
Introduction: Multiple myeloma (MM) is a plasma cell neoplasm with substantial morbidity and mortality. A comprehensive description of the global burden of MM is needed to help direct health policy, resource allocation, research, and patient care. Objective: To describe the burden of MM and the availability of effective therapies for 21 world regions and 195 countries and territories from 1990 to 2016. Design and Setting: We report incidence, mortality, and disability-adjusted life-year (DALY) estimates from the Global Burden of Disease 2016 study...
September 1, 2018: JAMA Oncology
https://www.readbyqxmd.com/read/29795433/prevention-and-treatment-of-relapse-after-stem-cell-transplantation-in-lymphoid-malignancies
#20
Anna Sureda, Peter Dreger, Michael R Bishop, Nicolaus Kroger, David L Porter
Relapse is now the major cause of treatment failure after allogeneic HSCT (alloHSCT). Many novel strategies to address this critical issue are now being developed and tested. At the 3rd International Workshop on Biology, Prevention, and Treatment of Relapse held in Hamburg, Germany in November 2016, international experts presented and discussed recent developments in the field. Some approaches may be applicable to a wide range of patients after transplant, whereas some may be very disease-specific. We present a report from the session dedicated to issues related to prevention and treatment of relapse of lymphoid malignancies after alloHSCT...
May 24, 2018: Bone Marrow Transplantation
keyword
keyword
164686
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"